179,500 Shares in Drugs Made In America Acquisition II Corp. $DMII Bought by GABELLI & Co INVESTMENT ADVISERS INC.

GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 179,500 shares of the company’s stock, valued at approximately $1,790,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC purchased a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth $265,000. Virtu Financial LLC purchased a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $317,000. ABC Arbitrage SA purchased a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $396,000. Deltec Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at about $495,000. Finally, Royal Bank of Canada acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at about $655,000.

Drugs Made In America Acquisition II Stock Performance

DMII stock opened at $10.10 on Friday. The company has a 50 day moving average of $10.08. Drugs Made In America Acquisition II Corp. has a 1 year low of $9.86 and a 1 year high of $10.11.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DMII. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.